Mission Connection has released a usage guide on olanzapine (Zyprexa), covering side effects and possible withdrawal symptoms that may occur if patients stop taking it.

San Juan Capistrano, United States, November 24, 2025 -- The latest guide from Mission Connection details FDA-approved uses of Zyprexa, metabolic risks, withdrawal protocols, and alternative treatments to support informed patient decisions. The guide is intended for individuals who may have been prescribed the drug after being diagnosed with schizophrenia, bipolar disorder, or other mental health and behavioral conditions that can alter moods or cause mania.

More information is available at https://missionconnectionhealthcare.com/mental-health/antipsychotics/zyprexa/

Schizophrenia and bipolar disorder affect millions globally, significantly impairing quality of life by disrupting thought, mood, and behavior, explains the mental health team. Though the conditions are distinct, both have overlapping symptoms, such as psychosis, disorganized thinking, and depressive episodes, which is why olanzapine is often prescribed to manage both disorders.

Olanzapine functions by modulating dopamine and serotonin levels, neurotransmitters that influence mood, behavior, and thought processes. The FDA has approved Zyprexa, a brand of olanzapine, for treating mixed episodes in bipolar disorder and schizophrenia in patients over 13; it has also been approved for use with the SSRI fluoxetine in treatment-resistant depression or depression associated with certain bipolar types.

According to Mission Connection’s guide, Zyprexa can also be used safely with lithium or valproate, which is effective at alleviating acute mania and preventing manic relapse; however, long-term use of the drug can cause adverse side effects that may impact an individual’s decision to take it.

Research shows olanzapine has the highest propensity for weight gain among antipsychotics, as it may increase the user’s appetite; other side effects include drowsiness, restlessness, constipation, and dry mouth.

Additionally, Zyprexa may cause chronic insomnia or fatigue, but Mission Connection’s guide notes that its effects on sleep quality are less pronounced compared to other antipsychotics; instead, patients should consider the increased risk of developing extrapyramidal symptoms (EPS), diabetes, and tardive dyskinesia before deciding whether they want to take the medication over a prolonged period of time.

Mission Connection also warns that patients who stop taking Zyprexa abruptly may experience nausea, tremors, anxiety, sleep disturbances, and, in some cases, emergent psychosis. Withdrawal symptoms can last from two weeks to several years, with duration varying based on dosage and length of treatment.

Individuals who want to stop Zyprexa are recommended to taper off the drug under clinical supervision to ensure that they can receive medical guidance in the event of severe withdrawal.

For more details, visit https://missionconnectionhealthcare.com/

Contact Info:
Name: Nathan Di Tomaso
Email: Send Email
Organization: Mission Connection
Address: 30310 Rancho Viejo Rd. , San Juan Capistrano, California 92675, United States
Website: https://missionconnectionhealthcare.com/

Source: PressCable

Release ID: 89176879

Should you identify any discrepancies, concerns, or inaccuracies in the content provided in this press release or require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team is committed to addressing your concerns within 8 hours by taking necessary actions to resolve identified issues diligently or guiding you through the necessary steps for removal. Our dedication lies in providing accurate and reliable information.